Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S; Gruppo Oncologico dell’Italia Meridionale (GOIM). Orlando L, et al. Among authors: antoniol g. Breast. 2024 Jun;75:103725. doi: 10.1016/j.breast.2024.103725. Epub 2024 Apr 5. Breast. 2024. PMID: 38615483 Free PMC article. Clinical Trial.
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.
Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, Perrone A, Zito Marino F, Panarese I, Tathode MS, Caraglia M, Gatta G, Ruggiero R, Parisi S, De Vita F, Ciardiello F, Docimo L, Orditura M. Iovino F, et al. Among authors: antoniol g. J Clin Med. 2022 Nov 26;11(23):6987. doi: 10.3390/jcm11236987. J Clin Med. 2022. PMID: 36498560 Free PMC article.
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.
Carlino F, Diana A, Ventriglia A, Piccolo A, Mocerino C, Riccardi F, Bilancia D, Giotta F, Antoniol G, Famiglietti V, Feliciano S, Cangiano R, Lobianco L, Pellegrino B, De Vita F, Ciardiello F, Orditura M. Carlino F, et al. Among authors: antoniol g. Cancers (Basel). 2022 Oct 11;14(20):4981. doi: 10.3390/cancers14204981. Cancers (Basel). 2022. PMID: 36291765 Free PMC article.
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.
Diana A, Carlino F, Buono G, Antoniol G, Famiglietti V, De Angelis C, Carrano S, Piccolo A, De Vita F, Ciardiello F, Daniele B, Arpino G, Orditura M. Diana A, et al. Among authors: antoniol g. Front Oncol. 2022 Mar 28;12:813462. doi: 10.3389/fonc.2022.813462. eCollection 2022. Front Oncol. 2022. PMID: 35419293 Free PMC article.
Vaccines in Children with Inflammatory Bowel Disease: Brief Review.
Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Esposito S, et al. Among authors: antoniol g. Vaccines (Basel). 2021 May 11;9(5):487. doi: 10.3390/vaccines9050487. Vaccines (Basel). 2021. PMID: 34064576 Free PMC article. Review.
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.
Morgillo F, De Vita F, Antoniol G, Orditura M, Auriemma PP, Diadema MR, Lieto E, Savastano B, Festino L, Laterza MM, Fabozzi A, Ventriglia J, Petrillo A, Ciardiello F, Barbarisi A, Iovino F. Morgillo F, et al. Among authors: antoniol g. Curr Oncol. 2013 Aug;20(4):e283-8. doi: 10.3747/co.20.1380. Curr Oncol. 2013. PMID: 23904766 Free PMC article.
16 results